Enanta Pharmaceuticals, Inc. ist eine Aktie aus dem Premium-Bereich von aktien.guide. Bitte anmelden, um einen Alarm für Enanta Pharmaceuticals, Inc. zu aktivieren.
Kostenlos registrieren
Bitte registriere Dich kostenlos, um Enanta Pharmaceuticals, Inc. zu Deinem Portfolio hinzuzufügen.
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that data for zelicapavir, its oral, once-daily, N-protein inhibitor, and EDP-323, it's oral, once-daily L-protein inhibitor, both in development for the treatment ...
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that it has closed its previously announced underwritten public offering of 7,475,000 shares of its common stock, which includes 975,000 shares sold pursuant to the underw...
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the pricing of an upsized underwritten public offering of 6,500,000 shares of its common stock at a public offering price of $10.00 per share. All of the shares are being offered ...
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced it has commenced an underwritten public offering for $50.0 million of shares of its common stock. All of the shares are being offered by Enanta. In addition, Enanta intends to gra...
Enanta Pharmaceuticals, Inc. - Special Call Company Participants Jennifer Viera - Executive Director of Investor Relations & Corporate Communications Jay Luly - President, CEO & Director Scott Rottinghaus - Chief Medical Office Conference Call Participants Brandon Folkes - H.C. Wainwright & Co, LLC, Research Division Antonio Arce - WestPark Capital, Inc., Research Division Brian Skorney - Rober...
Enanta Pharmaceuticals remains a Buy as zelicapavir shows multiple positive efficacy endpoints in RSV despite missing its primary endpoint in the phase 2b study. Zelicapavir demonstrated statistically significant improvements in PGI-S scores and viral load reduction, supporting potential for phase 3 advancement pending FDA feedback. Strong cash position funds operations into 2028, with ongoing...
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced positive topline data from RSVHR, a Phase 2b, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of zelicapavir in outpatient adults w...
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced the company will hold a conference call and webcast on Monday, September 29 at 8:30 a.m. ET to share topline results from RSVHR, a Phase 2b study evaluating zelicapavir fo...
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.